Recro Pharma Inc (REPH) Expected to Announce Earnings of -$0.79 Per Share
Brokerages expect Recro Pharma Inc (NASDAQ:REPH) to announce earnings of ($0.79) per share for the current fiscal quarter, Zacks Investment Research reports. Two analysts have provided estimates for Recro Pharma’s earnings. The lowest EPS estimate is ($0.84) and the highest is ($0.74). Recro Pharma posted earnings per share of ($0.81) in the same quarter last year, which would indicate a positive year over year growth rate of 2.5%. The company is scheduled to issue its next quarterly earnings results on Monday, March 5th.
According to Zacks, analysts expect that Recro Pharma will report full-year earnings of ($2.15) per share for the current year, with EPS estimates ranging from ($2.20) to ($2.10). For the next fiscal year, analysts anticipate that the business will post earnings of ($2.99) per share, with EPS estimates ranging from ($4.31) to ($2.12). Zacks Investment Research’s EPS calculations are an average based on a survey of sell-side analysts that that provide coverage for Recro Pharma.
Recro Pharma (NASDAQ:REPH) last released its quarterly earnings data on Thursday, November 9th. The specialty pharmaceutical company reported ($0.48) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.75) by $0.27. Recro Pharma had a negative net margin of 51.88% and a negative return on equity of 60.01%.
Recro Pharma (REPH) traded up $0.04 during mid-day trading on Tuesday, reaching $8.93. 163,894 shares of the company’s stock were exchanged, compared to its average volume of 119,885. The firm has a market cap of $170.78, a P/E ratio of -4.15 and a beta of -0.50. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.35 and a current ratio of 1.59. Recro Pharma has a 12 month low of $5.81 and a 12 month high of $10.59.
In other news, major shareholder Scp Vitalife Partners Ii Lp sold 18,231 shares of the firm’s stock in a transaction that occurred on Friday, December 29th. The shares were sold at an average price of $9.27, for a total transaction of $169,001.37. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Healthcare Master Fun Broadfin sold 102,440 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was sold at an average price of $9.50, for a total transaction of $973,180.00. The disclosure for this sale can be found here. Insiders have sold a total of 860,414 shares of company stock valued at $8,289,916 in the last 90 days. Insiders own 21.60% of the company’s stock.
Several hedge funds and other institutional investors have recently made changes to their positions in REPH. OxFORD Asset Management LLP increased its holdings in shares of Recro Pharma by 364.3% during the 2nd quarter. OxFORD Asset Management LLP now owns 203,430 shares of the specialty pharmaceutical company’s stock worth $1,430,000 after buying an additional 159,619 shares during the last quarter. State Street Corp acquired a new stake in shares of Recro Pharma during the 2nd quarter worth approximately $1,047,000. Northern Trust Corp increased its holdings in shares of Recro Pharma by 428.5% during the 2nd quarter. Northern Trust Corp now owns 178,437 shares of the specialty pharmaceutical company’s stock worth $1,254,000 after buying an additional 144,676 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in shares of Recro Pharma by 787.4% during the 2nd quarter. Dimensional Fund Advisors LP now owns 129,560 shares of the specialty pharmaceutical company’s stock worth $911,000 after buying an additional 114,960 shares during the last quarter. Finally, JT Stratford LLC purchased a new position in shares of Recro Pharma during the 2nd quarter worth approximately $704,000. Institutional investors and hedge funds own 61.55% of the company’s stock.
About Recro Pharma
Recro Pharma, Inc is a clinical-stage specialty pharmaceutical company. The Company is engaged in developing products for hospitals and ambulatory care settings that is developing non-opioid products for treatment of serious acute pain. The Company’s lead product candidate is an injectable form of meloxicam.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Recro Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Recro Pharma and related companies with MarketBeat.com's FREE daily email newsletter.